Maze Therapeutics Reports Q3 2026 Results, $477 Million in Cash
Maze Therapeutics reported a third-quarter 2026 net loss of $48.0 million, versus $30.1 million a year earlier, and held $477.0 million in cash, cash equivalents and marketable securities at quarter-end. It recognized no license revenue.
Maze Therapeutics reported a third-quarter 2026 net loss of $48.0 million, compared with $30.1 million a year earlier, and held $477.0 million in cash, cash equivalents and marketable securities at quarter-end. The company recognized no license revenue in the quarter and reported $20.0 million for…